Immunotherapy in malignant melanoma: recent approaches and new perspectives.

IF 1 Q4 ONCOLOGY

Melanoma Management Pub Date : 2017-03-01 DOI:10.2217/mmt-2016-0019

Hugo Arasanz, Alejandra Lacalle, Maria José Lecumberri, Ángela Fernández de Lascoiti, Idoia Blanco-Luquin, María GatoCañas, Leyre Pérez-Ricarte, Miren Zuazo, Grazyna Kochan, David Escors

引用次数: 0

Abstract

Immunotherapy has radically transformed the management of metastatic malignant melanoma. Ipilimumab, a CTLA-4-targeted monoclonal antibody, was the first immunotherapeutic drug to reach a survival benefit compared with traditional chemotherapy. PD-1 targeted therapies, pembrolizumab and nivolumab, have demonstrated, in recent clinical trials, to be even more effective and safer. PD-1 and CTLA-4 blockade combination appears to improve the outcomes achieved so far, although increasing toxicity. However, many questions concerning the optimal timing of administration or the most adequate sequence of treatment are yet to be answered.

Abstract Image

查看原文本刊更多论文

恶性黑色素瘤的免疫治疗：最新方法和新观点。

免疫治疗从根本上改变了转移性恶性黑色素瘤的治疗。Ipilimumab是一种CTLA-4靶向单克隆抗体，是第一种与传统化疗相比具有生存益处的免疫治疗药物。PD-1靶向疗法，pembrolizumab和nivolumab，在最近的临床试验中已经证明更有效、更安全。PD-1和CTLA-4阻断剂的组合似乎改善了迄今为止取得的结果，尽管毒性增加。然而，关于最佳给药时间或最适当的治疗顺序的许多问题还有待回答。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.